Intel, MeitY's IndiaAI ink pact to drive AI skilling across India
Intel
and the Ministry of Electronics & IT's (
MeitY
) IndiaAI have signed a memorandum of understanding (MoU) to jointly drive
artificial intelligence
(AI) capabilities and skilling in India under the
IndiaAI Mission
.
The pact between the organisations aims to empower youth, professionals, startups, and public sector firms to harness AI's potential and advance AI readiness, enable the
AI startup ecosystem
, and strengthen AI-led governance in India, according to a joint statement on Friday.
The Prime Minister Narendra Modi-led government last year had approved the IndiaAI Mission with a budgetary outlay of ₹10,371.92 crore, with a focus on catalysing AI innovation through strategic programs and partnerships across the public and private sectors.
The national-level AI initiative aims to democratise computing access, improve data quality, develop indigenous AI capabilities, attract top AI talent, enable industry collaboration, and provide startup risk capital, to ensure inclusive growth of India's AI ecosystem.
Intel and IndiaAI, an independent business unit under the Digital India Corporation, will jointly focus on four programmes, including skilling school students and higher education students to improve their employability; providing access to technology, business, and go-to-market mentorship to AI startups; engaging in dialogues with public sector leaders; and enabling Bhashini for scaling to remote classrooms across India on AI PCs.
'This strategic collaboration between Intel India and the IndiaAI Mission marks a significant milestone in developing a robust AI ecosystem across the country. By equipping students, startups, and public sector leaders with cutting-edge AI skills and frugal innovation tools, we aim to accelerate innovation, break down barriers and generate positive societal impact,' said
Santhosh Viswanathan
, vice president and managing director (India region), Intel.
'The collaboration with Intel India is helping set up data lab to train youth in data science and Artificial Intelligence. Our partnership with Intel for YuvaAI has helped train thousands of students in basics of Artificial Intelligence. We look forward to working with Intel to get the best of their global technical experts in contributing to India AI Mission,' said
Abhishek Singh
, additional secretary, MeitY & CEO, IndiaAI Mission.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
an hour ago
- Economic Times
India should avoid rushing for trade pact with US, warn experts
Synopsis Experts caution India against rushing into a trade deal with the US, potentially compromising crucial sectors like agriculture. The US's aggressive tactics, including imposing tariffs on key partners like the EU, highlight the risk of unbalanced agreements. Despite US pressure, many nations resist one-sided terms, urging India to proceed cautiously and protect its core interests during negotiations. Getty Images India should avoid rushing into a trade deal with the US that compromises core sectors like agriculture, experts on Sunday said, cautioning that Washington is not sparing even its key partners like the EU. The US has shot off letters to 24 countries and the European Union (EU) imposing tariffs that are as high as 50 per cent on Brazil. On its key trading partners like the EU and Mexico, 30 per cent duties have been proposed from August 1. Economic think tank GTRI (Global Trade Research Initiative) said India must recognise that it is not alone in facing US pressure. The US is currently negotiating with over 20 countries and seeking concessions from more than 90. "Yet most are resisting because they see these MASALA (Mutually Agreed Settlements Achieved through Leveraged Arm-twisting) deals for what they are politically driven, transactional demands offering no lasting trade certainty," GTRI Founder Ajay Srivastava said. He added that both the EU and Mexico are major trade partners of the US, and Washington can impose tariffs on them to pressure them into quick deals, India cannot expect a balanced deal. Another trade expert said India should tread cautiously while negotiating the trade pact with the US. The expert added that Trump's trade threat is rapidly losing credibility as despite more than three months of pressure, only two countries -- the UK and Vietnam -- have agreed to the USA's one-sided terms. From Japan and South Korea to the EU and Australia, countries are resisting Trump's trade deals that demand tariff cuts without reciprocal US concessions, mandate guaranteed purchases of American goods, and leave the door open for future tariffs even after a deal is signed, the GTRI said. A team of Indian trade negotiators will soon visit Washington to further talks for the proposed Bilateral Trade Agreement (BTA). "India should stay the course and avoid trading away core sectors like agriculture. A hasty deal under pressure could have irreversible consequences, especially when such agreements may not survive the next shift in US politics," Srivastava said.
Hindustan Times
an hour ago
- Hindustan Times
Trump Says 200% Pharma Tariffs Are Coming. Wall Street Shrugs.
But since Tuesday, when Donald Trump said in a cabinet meeting that imported pharmaceuticals would face a massive levy, investors have been cautiously celebrating. Despite a broad stock selloff on Friday, the NYSE Arca Pharmaceutical Index is up around 1% over the past week, compared with a basically flat performance for the S&P 500. That outperformance may seem puzzling, but for Wall Street, the size of the tariff matters less than the timing. The 200% figure lit up cable news chyrons, but investors focused instead on the grace period Trump floated. 'We're going to give people about a year, year and a half to come in, and after that, they're going to be tariffed,' he said. A year and a half is a long runway—and it could turn out to be even longer in practice. In a note titled 'Tariffs Schmariffs,' Jefferies analyst Akash Tewari argues that if the grace period begins some time this year and lasts for a year and a half, companies could continue importing drugs tariff-free until 2027. They could buy even more time if they stockpile during that period to cover demand at least until some time in 2028. That might give them time to build entirely new U.S. manufacturing facilities, which typically takes around four years. This doesn't mean Trump isn't getting what he wants. After all, the tariffs are meant as a threat to push companies to make more of their products in the U.S. And in this case, the threat seems to be working. Since Trump began threatening pharma with tariffs, the industry has moved on two fronts. First, companies have been stockpiling drugs at a furious pace to build a cushion. For instance, the Wall Street Journal reported last month that $36 billion worth of hormone treatments—used in popular obesity and diabetes drugs—have been shipped from Ireland this year, more than double last year's total. Second, the industry has announced major investments in U.S. manufacturing. Some of that may be political posturing, but much of it reflects a real shift. Companies increasingly see no choice but to bring production back, at least for drugs sold to American patients. Eli Lilly, for example, has announced a $27 billion plan to expand manufacturing in the U.S. Making drugs in the U.S.—and registering the intellectual property here—comes with a tax hit. That is a big reason the industry offshored production to low-tax countries like Ireland in the first place. But Trump's 'Big Beautiful Bill' offers some relief to offset the pain. The bill lets companies immediately deduct R&D expenses and equipment purchases and raises the cap on how much interest they can write off—making it a lot cheaper to build new plants at home. The upshot: with more time to prepare and a friendlier tax environment, pharma companies may barely feel the sting of tariffs. Take Merck. The company plans to produce a new version of its blockbuster drug Keytruda in the U.S. Jefferies estimates that with steps like stockpiling, gradually shifting production and trimming some costs, the hit to Merck's earnings from tariffs in 2027 and 2028 could be just 1% to 2%. That is actually better than Jefferies's earlier model for a smaller 25% tariff, which assumed fewer workarounds. The sense of a new normal settling in around Trump's second presidency might help explain why dealmaking has returned to the sector. Merck this past week announced a roughly $10 billion deal to buy Verona Pharma. That followed a series of other deal announcements, including Eli Lilly's $1.3 billion pact to acquire Verve Therapeutics. By the end of Trump's term, the U.S. pharmaceutical supply chain could look very different, with a greater share of innovative drug production happening on American soil. That would be a rare win-win—for the White House and for the industry. Write to David Wainer at
India Gazette
2 hours ago
- India Gazette
MP CM Yadav holds talks with Indian business delegation in Dubai
Dubai [UAE], July 13 (ANI): Madhya Pradesh CM Mohan Yadav on Sunday engaged in detailed discussions with members of the Indori International Business Network (IIBN) under the 'Madhya Pradesh Global Dialogue 2025' in Dubai. Yadav talked about prospects for mutual cooperation in Madhya Pradesh. In a post on X, he said, 'Under the 'Madhya Pradesh Global Dialogue 2025', today in Dubai, I engaged in detailed discussions with esteemed members of the Indori International Business Network (IIBN) about the immense investment opportunities, cultural exchange, and prospects for mutual cooperation in Madhya Pradesh. It was immensely gratifying to note that IIBN representatives expressed a deep desire to reconnect with their hometowns and showed keen interest in establishing businesses in cities like Bhopal, Dewas, Ujjain, Dhar, and Pithampur. A hearty welcome to the global industrial community in the 'Heart of India'!' Yadav while holding talks with Indian Business Delegation who hails from Madhya Pradesh said that under the leadership of Prime Minister Narendra Modi, the times are in favour of India. Yadav said that times are changing quickly and the country is working to keep up with it. 'Under the leadership of the glorious Prime Minister, the scenario has changed in a way... There is also a need to move in such a way as to relate to the work we are doing here because that time is moving very quickly in the changing times. India's time is very favorable in this changing era,' he said. He said that Prime Minister Narendra Modi is maintaining the beauty of the modern world, which is the speciality of a democratic country. 'Today's time under the leadership of Honorable Modi is maintaining the beauty of our world, which is the speciality of a democratic country, where the rights of the people are held by the people and many other pyramids have changed,' he said. Yadav acknowledged that the diaspora has worked hard for Indians as well and established themselves there. 'People are doing their job here for us too... You all have worked hard for so many days and made your place here. And it is good that you have that it in your hearts,' he said. (ANI)
